RG
NKTR icon

Redmile Group’s Nektar Therapeutics NKTR Stock Holding History

Redmile Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-355
Closed -$318K – 70
2017
Q4 		$318K Sell
355
-617
-63% -$365K 0.01% 62
2017
Q3 		$350K Hold
972
– – 0.02% 61
2017
Q2 		$285K Buy
+972
New +$281K 0.02% 59

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Redmile Group's NKTR Position: Q1 2018 in Review

Redmile Group sold out of Nektar Therapeutics (NKTR) in Q1 2018, closing a stake of 355 shares — an estimated $318K sold.

Redmile Group first reported a position in NKTR in Q2 2017 and held it in 3 quarters. The position peaked at $350K in Q3 2017. 359 funds tracked by Wall St. Rank hold NKTR as of Q1 2018.

  • Redmile Group reported no remaining Nektar Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Redmile Group sold 355 Nektar Therapeutics shares in Q1 2018, an estimated $318K.
  • Redmile Group first reported a position in Nektar Therapeutics in Q2 2017 and held it in 3 quarters.
  • Redmile Group's Nektar Therapeutics position peaked at $350K in Q3 2017.
  • 359 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2018.

Based on Redmile Group's 13F filing for Q1 2018, filed 15 May 2018.